These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 37351275)
1. Characterization of cuproptosis in gastric cancer and relationship with clinical and drug reactions. Chen G; Luo D; Qi X; Li D; Zheng J; Luo Y; Zhang C; Ren Q; Lu Y; Chan YT; Chen B; Wu J; Wang N; Feng Y Front Cell Dev Biol; 2023; 11():1172895. PubMed ID: 37351275 [TBL] [Abstract][Full Text] [Related]
2. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma. Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X Front Oncol; 2023; 13():1152681. PubMed ID: 37333810 [TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201 [TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma. Li J; Yin J; Li W; Wang H; Ni B Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma. Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062 [TBL] [Abstract][Full Text] [Related]
7. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma. Li Y; Zeng X Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728 [No Abstract] [Full Text] [Related]
8. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer. Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X Front Oncol; 2023; 13():1083956. PubMed ID: 37384293 [TBL] [Abstract][Full Text] [Related]
9. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma. He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949 [No Abstract] [Full Text] [Related]
10. Identification of Cuproptosis-Related Subtypes, Establishment of a Prognostic Signature and Characterization of the Tumor Microenvironment in Gastric Cancer. Li J; Kong C; Song W; Fu T Int J Gen Med; 2023; 16():1631-1652. PubMed ID: 37168531 [TBL] [Abstract][Full Text] [Related]
11. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma. Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226 [TBL] [Abstract][Full Text] [Related]
12. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma. Chen X; Hu G; Xiong L; Xu Q Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162 [No Abstract] [Full Text] [Related]
13. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer. Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115 [TBL] [Abstract][Full Text] [Related]
14. A cuproptosis-related signature for predicting the prognosis of gastric cancer. He C; Zhang H; Guo Z; Mo Z J Gastrointest Oncol; 2023 Feb; 14(1):146-164. PubMed ID: 36915443 [TBL] [Abstract][Full Text] [Related]
15. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma. Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L Front Genet; 2023; 14():1056000. PubMed ID: 36845390 [No Abstract] [Full Text] [Related]
16. Evaluation the role of cuproptosis-related genes in the pathogenesis, diagnosis and molecular subtypes identification of atherosclerosis. Wang M; Cheng L; Xiang Q; Gao Z; Ding Y; Xie H; Chen X; Yu P; Shen L Heliyon; 2023 Oct; 9(10):e21158. PubMed ID: 37928399 [TBL] [Abstract][Full Text] [Related]
17. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma. Zhang Y; Zhou J; Li H; Liu Y; Li J BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC. Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J Front Genet; 2023; 14():1094793. PubMed ID: 36891150 [No Abstract] [Full Text] [Related]
19. Identification of novel molecular subtypes and a signature to predict prognosis and therapeutic response based on cuproptosis-related genes in prostate cancer. Zhang J; Jiang S; Gu D; Zhang W; Shen X; Qu M; Yang C; Wang Y; Gao X Front Oncol; 2023; 13():1162653. PubMed ID: 37205181 [TBL] [Abstract][Full Text] [Related]
20. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP Front Immunol; 2022; 13():933973. PubMed ID: 36045691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]